Psychiatry Research: Neuroimaging
Volume 172, Issue 1 , Pages 38-43 , 30 April 2009

Imaging the serotonin transporter using 123I-ADAM in the human brain

  • Yuan-Hwa Chou

      Affiliations

    • Department of Psychiatry, Taipei Veterans General Hospital & National Yang Ming University, Taipei, Taiwan
    • ,
  • Bang-Hung Yang

      Affiliations

    • Department of Nuclear Medicine, Taipei Veterans General Hospital & National Yang Ming University, Taipei, Taiwan
    • ,
  • Ming-Yi Chung

      Affiliations

    • Faculty of Life Sciences & Institute of Genome Sciences, National Yang Ming University, Taipei, Taiwan
    • dDepartment of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan
    • ,
  • Shih-Pei Chen

      Affiliations

    • Department of Nuclear Medicine, Taipei Veterans General Hospital & National Yang Ming University, Taipei, Taiwan
    • ,
  • Tung-Ping Su

      Affiliations

    • Department of Psychiatry, Taipei Veterans General Hospital & National Yang Ming University, Taipei, Taiwan
    • ,
  • Chia-Chieh Chen

      Affiliations

    • eInstitute of Nuclear Energy Research, Lung-Tan, Taoyuan, Taiwan
    • ,
  • Shyh-Jen Wang

      Affiliations

    • Department of Nuclear Medicine, Taipei Veterans General Hospital & National Yang Ming University, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Taipei Veterans General Hospital, No 201, Sec 2, Shih-Pai Rd, 112, Peitou, Taipei, Taiwan. Tel.: +886 2 2871 1290; fax: +886 2 2871 5849.

Received 25 August 2007 ,Revised 12 November 2008 ,Accepted 28 December 2008.

References 

  1. Acton PD, Choi SR, Hou C, Plossl K, Kung HF. Quantification of serotonin transporters in nonhuman primates using [(123)I]ADAM and SPECT. Journal of Nuclear Medicine. 2001;42:1556–1562
  2. Ashburner J, Andersson JL, Friston KJ. High-dimensional image registration using symmetric priors. Neuroimage. 1999;9:619–628
  3. Ashburner J, Andersson JL, Friston KJ. Image registration using a symmetric prior—in three dimensions. Human Brain Mapping. 2000;9:212–225
  4. Booij J, Knol RJ, Reneman L, de Bruin K, Janssen AG, van Royen EA. Iodine-123 labelled nor-beta-CIT binds to the serotonin transporter in vivo as assessed by biodistribution studies in rats. European Journal of Nuclear Medicine. 1998;25:1666–1669
  5. Catafau AM, Perez V, Penengo MM, Bullich S, Danus M, Puigdemont D, et al. SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test–retest in healthy volunteers. Journal of Nuclear Medicine. 2005;46:1301–1309
  6. Chalon S, Bronquard C, Vercouillie J, Kodas E, Garreau L, Bodard S, et al. ADAM is an effective tool for in vivo study of serotonergic function: validation in rat models. Synapse. 2004;52:136–142
  7. Choi SR, Hou C, Oya S, Mu M, Kung MP, Siciliano M, et al. Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse. 2000;38:403–412
  8. Chou YH, Halldin C, Farde L. Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: a PET study. Synapse. 2000;38:138–143
  9. Chou YH, Halldin C, Farde L. Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology. 2003;166:234–240
  10. Chou YH, Halldin C, Farde L. Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology. 2006;185:29–35
  11. Chou YH, Karlsson P, Halldin C, Olsson H, Farde L. A PET study of D(1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. Psychopharmacology. 1999;146:220–227
  12. Chou YH, Huang WS, Su TP, Lu RB, Wan FJ, Fu YK. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: a SPECT study. European Neuropsychopharmacology. 2007;17:46–52
  13. Cortes R, Soriano E, Pazos A, Probst A, Palacios JM. Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine. Neuroscience. 1988;27:473–496
  14. Eglen RM, Wong EH, Dumuis A, Bockaert J. Central 5-HT4 receptors. Trends in Pharmacological Sciences. 1995;16:391–398
  15. Erlandsson K, Sivananthan T, Lui D, Spezzi A, Townsend CE, Mu S, et al. Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. European Journal of Nuclear Medicine & Molecular Imaging. 2005;32:1329–1336
  16. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986;231:258–261
  17. Farde L, Eriksson L, Blomquist G, Halldin C. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET—a comparison to the equilibrium analysis. Journal of Cerebral Blood Flow & Metabolism. 1989;9:696–708
  18. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Archives of General Psychiatry. 1990;47:213–219
  19. Frokjaer VG, Pinborg LH, Madsen J, de Nijs R, Svarer C, Wagner A, et al. Evaluation of the serotonin transporter ligand 123I-ADAM for SPECT Studies on humans. [see comment]. Journal of Nuclear Medicine. 2008;49:247–254
  20. Halldin C, Foged C, Chou YH, Karlsson P, Swahn CG, Sandell J, et al. Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. Journal of Nuclear Medicine. 1998;39:2061–2068
  21. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. Journal of Neurochemistry. 1996;66:2621–2624
  22. Hesse S, Barthel H, Schwarz J, Sabri O, Muller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neuroscience & Biobehavioral Reviews. 2004;28:547–563
  23. Ito H, Hietala J, Blomqvist G, Halldin C, Farde L. Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. Journal of Cerebral Blood Flow & Metabolism. 1998;18:941–950
  24. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?. Nuclear Medicine & Biology. 2005;32:123–128
  25. Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R, et al. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology. 2006;188:263–272
  26. Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T, Lanzenberger R, et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology. 2007;191:333–339
  27. Kroeze WK, Roth BL. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biological Psychiatry. 1998;44:1128–1142
  28. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–158
  29. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, et al SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993;13:295–309
  30. Lee MS, Lee HY, Lee HJ, Ryu SH. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatric Genetics. 2004;14:111–115
  31. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. [see comment]. Science. 1996;274:1527–1531
  32. Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Progress in NeuroPsychopharmacology & Biological Psychiatry. 2005;29:1062–1073
  33. Lin KJ, Yen TC, Wey SP, Hwang JJ, Ye XX, Tzen KY, et al. Characterization of the binding sites for 123I-ADAM and the relationship to the serotonin transporter in rat and mouse brains using quantitative autoradiography. Journal of Nuclear Medicine. 2004;45:673–681
  34. Meneses A. 5-HT system and cognition.. Neuroscience & Biobehavioral Reviews. 1999;23:1111–1125
  35. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Annals of Neurology. 1984;15:217–227
  36. Newberg AB, Plossl K, Mozley PD, Stubbs JB, Wintering N, Udeshi M, et al. Biodistribution and imaging with (123)I-ADAM: a serotonin transporter imaging agent. Journal of Nuclear Medicine. 2004;45:834–841
  37. Ng CH, Easteal S, Tan S, Schweitzer I, Ho BK, Aziz S. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Progress in Neuro Psychopharmacology & Biological Psychiatry. 2006;30:953–957
  38. Olsson H, Farde L. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy—a simulation study based on experimental data. Neuroimage. 2001;14:936–945
  39. Oya S, Choi SR, Hou C, Mu M, Kung MP, Acton PD, et al. 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nuclear Medicine & Biology. 2000;27:249–254
  40. Parsey RV, Mann JJ. Applications of positron emission tomography in psychiatry.. Seminars in Nuclear Medicine. 2003;33:129–135
  41. Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. Journal of Nuclear Medicine. 2000;41:36–44
  42. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.. Psychopharmacology. 2004;174:17–24
  43. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Molecular Psychiatry. 2004;9:433–441
  44. van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, et al. Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. Neurobiology of Aging. 2000;21:497–501
  45. Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Human Brain Mapping. 2004;22:246–260
  46. Ye XX, Chen JC, Liu RS, Wey SP, Lee JS, Chen CC, et al. Microautoradiography of [123I]ADAM in mice treated with fluoxetine and serotonin reuptake inhibitors. Nuclear Medicine & Biology. 2004;31:557–562
  47. Zeng Z, Chen TB, Miller PJ, Dean D, Tang YS, Sur C, et al. The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites. Nuclear Medicine & Biology. 2006;33:555–563

PII: S0925-4927(09)00002-X

doi: 10.1016/j.pscychresns.2008.12.006

Psychiatry Research: Neuroimaging
Volume 172, Issue 1 , Pages 38-43 , 30 April 2009

Article Tools

* Image Usage & Resolution